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Urothelial carcinoma of the upper urinary tract represents only 5% of all urothelial cancers. The 5-year cancer-speciﬁc survival
in the United States is roughly 75% with grade and stage being the most powerful predictors of survival. Nephroureterectomy
with excision of the ipsilateral ureteral oriﬁce and bladder cuﬀ en bloc remains the gold standard treatment of the upper
urinary tract urothelial cancers, while endoscopic and laparoscopic approaches are rapidly evolving as reasonable alternatives
of care depending on grade and stage of disease. Several controversies remain in their management, including a selection of
endoscopic versus laparoscopic approaches, management strategies on the distal ureter, the role of lymphadenectomy, and the
value of chemotherapy in upper tract disease. Aims of this paper are to critically review the management of such tumors, including
endoscopic management, laparoscopic nephroureterectomy and management of the distal ureter, the role of lymphadenectomy,
and the emerging role of chemotherapy in their treatment.
Copyright © 2009 Georgios Koukourakis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Primary urothelial carcinoma of the upper tract is a rare
urological disease and has a propensity for multifocality,
local recurrence, and development of metastases. Almost 5%
of all urothelial neoplasms occur in the kidney and ureters.
The vast majority of upper tract tumors arise in the kidney,
comprising 4% to 15% of all primary kidney neoplasms in
theUnitedStates,whereasureteraltumorsrepresentonly1%
[1].
As a result, urothelial carcinoma of the bladder has
been examined to a greater extent than urothelial tumors
elsewhere.
The main treatment for patients with upper tract urothe-
lial neoplasms and a normal contralateral kidney is a com-
plete nephroureterectomy with removal of a cuﬀ of urinary
bladder. Due to the high rate of ureteral stump recurrence,
which has been reported to be between 30% and 75%, it is
important to complete the nephroureterectomy with a cuﬀ
of urinary bladder [2–10]. Hall et al. [11]r e p o r t e di no n e
of the largest series in the literature on 252 patients who
were treated for upper tract urothelial tumors with a median
follow-up of 64 months. One hundred ninety-four (76.6%)
patients underwent open radical nephroureterectomy with
removal of bladder cuﬀ, 42 (16.7%) patients underwent
parenchymal-sparing surgery, 14 (5.6%) patients under-
went nephrectomy alone, and 2 (0.8%) had exploration
only for nonresectable disease. Overall, patients undergoing
parenchymal-sparing surgery had a lower actuarial 5-year
disease-free survival rate than those treated with initial2 Advances in Urology
Table 1: Studies that compare laparoscopic nephroureterectomy with open surgery.
Study No. of
patients Tumor grade Follow-up Outcomes
Gill et al. [12] 42 in LT,
35 in OS
34 patients in LT arm
and 28 in OS arm III
tumors
11.1 months in
LT,34.4 in OS
LT signiﬁcantly decreasing
morbidity with comparable
oncological and survival
data to OS
Shalhav et al. [13] 25 in LT
17 in OS
21 patients in LT arm
and 14 in OS arm
grade II
2 years in both arms
LT has longer operating
time but the same eﬃcacy
a n di sb e t t e rt o l e r a t e d
LT: laparoscopic treatment, OS: open surgery.
aggressive surgical resection (23% versus 45%, P<. 0009).
Patients with grades 1 and 2 tumors were equally distributed
in these 2 groups. This study supported the use of aggressive
open surgical resection for initial treatment of upper tract
urothelial tumors, with a 5-year disease-free survival rate of
45%.
Nevertheless, the gold standard of open radical neph-
roureterectomy with resection of a bladder cuﬀ is being chal-
lenged by minimally invasive approaches to the managing
of upper tract transitional cell carcinoma (TCC). For upper
tracturothelialcarcinoma,laparoscopicnephroureterectomy
has been used as an alternative to an open procedure.
Since the ﬁrst laparoscopic nephroureterectomy, performed
by Clayman in May 1991 at Washington University (St.
Louis, Mo, USA), numerous reports regarding the safety
and eﬃcacy of that procedure have been published [12, 14–
23]. This paper will cover the therapeutic approaches to
upper tract TCC, including laparoscopic nephroureterec-
tomy, endoscopic approaches, and the prognostic value of
lymphadenectomy in patients with muscle invasion. Topical
immunotherapy, adjuvantchemotherapy,andadjuvant radi-
ation therapy will also be discussed.
2.SurgicalTreatment
2.1. Laparoscopic Treatment. Recently, Gill et al. published
on their experience of 42 patients who underwent laparo-
scopic retroperitoneal nephroureterectomy with a mean
follow-up of 11.1 months [12]. The distal ureter was
treated with a combination of laparoscopic and endoscopic
transvesical approaches [23]. A comparable research was
performed between those patients and another 35, who
underwent open nephroureterectomy at their department.
In the laparoscopic group, the blood lost was signiﬁcantly
less (242 versus 696mL). Postsurgically, patients in the
laparoscopic group had a signiﬁcantly more rapid recom-
mencement of ambulation (1.4 versus 2.5 days), oral intake
(1.6 versus 3.2 days), shorter hospital stay (2.3 versus
6.6 days), decreased analgesic necessities (26mg morphine
sulfate equivalent versus 228mg), and a more rapid period
of recovery (8 versus 14.1 weeks). Complications occurred
in 5 (12%) and 10 (29%) patients in the laparoscopic and
open groups, respectively. These complications integrated
1 renal vein injury, 1 patient with ﬂuid extravasations
from mobilization of the bladder cuﬀ, and 3 patients with
atelectasis in the laparoscopic group. The open group had 4
patients with atelectasis, 5 patients with postoperative ileus,
and 1 patient with a pneumothorax. Two cases required
an open conversion because of a renal injury and an
electiveconversionsecondarytolocaltumorinﬁltrationwith
obliteration of tissue planes near the hilum.
The mean pathologic grade was 2.3 for both of the
groups, with the laparoscopic group having 9, 10, and 23
patients with grades 1, 2, and 3 tumors and the open
group having 6, 10, and 16 patients with grades 1, 2, and
3 tumors, respectively. Surgical margins were positive in
3 (7%) patients in the laparoscopic group and 5 (15%)
patients in the open group. All 3 patients in the laparoscopic
group received systemic chemotherapy postoperatively, and
pulmonary metastases developed in 1 patient during follow-
up. For comparable stage and grade of primary tumor, the
negative surgical margin rate was similar between the 2
groups. The two groups of laparoscopic and open surgeries
have no diﬀerence as regarding the bladder recurrence
(23 versus 37%), retroperitoneal or port site/incisional
recurrence (0 versus 0%), or distant metastases (8,6 versus
13%). There was no diﬀerence in either cancer-speciﬁc
survival (97% versus 87%) or crude survival (97% versus
94%) after adjusting for the shorter follow-up period (11
versus 34 months) between the laparoscopic and open
groups, respectively, during follow-up. Mortality occurred
in 2 patients (6%) of the laparoscopic group and in 6
of the open group (30%). The authors cannot estimate
whether these mortality rates are signiﬁcantly diﬀerent or
equivalent [12]. The results of the trails that compare
laparoscopic treatment with open surgery are summarized
in Table 1. The techniques of laparoscopic retroperitoneal
nephroureterectomy and partial nephrectomy are shown in
Figures 1(a), 1(b), and 1(c) and in Figure 2,r e s p e c t i v e l y .
Patients are placed in the full ﬂank position. Usually, the
operating table is ﬂexed and the kidney rest is elevated,
thereby increasing the space between the iliac crest and the
lowerribs.Retroperitonealaccessisobtainedthroughasmall
10- to 15-mm incision just below and medial to the tip
of the 12th rib (Figure 1(a)). The muscle and fascia are
separated using a blunt instrument that allows one ﬁnger
to develop a working space posterior to the kidney above
the psoas muscle (Figure 1(b)). Often the lower pole of
the kidney is immediately palpated. The colon is separated
away from the anterolateral abdominal wall with the indexAdvances in Urology 3
(a) (b) (c)
Figure 1: (a) Access for a right retroperitoneal laparoscopic radical nephrectomy (LRN). A 10- to 15-mm incision is made below and medial
to the tip of the 12th rib. (b) The ﬂank muscles are pierced with a blunt-tipped instrument followed by ﬁnger dissection and development
of the retroperitoneum space to permit trocar placement. (c) Trocar placement for a right retroperitoneal LRN.
Figure 2: Retroperitoneal laparoscopic left partial nephrectomy.
ﬁnger. Additional trocars are placed below the 12th rib just
above the psoas muscle posteriorly, and then more anteriorly
through the lateral abdominal wall under direct vision
using the laparoscope (Figure 1(c)). Laparoscopic partial
nephrectomy is ideal for a patient with an exophytic, small,
and peripherally located renal tumor (Figure 2).
The literature research discovered similar eﬀects in
transperitoneal laparoscopic nephroureterectomy [13, 24].
The familiarity with anatomic landmarks and a larger
working space are some advantages of transperitoneal
approach compared to retroperitoneal one. The retroperi-
toneal approach, however, has distinct advantages, for exam-
ple, permittance of early control of the renal artery and vein,
no manipulation of the bowel leading to less incidence of
ileus and possibly a shorter hospital stay, and conﬁnement
of possible urinomas or seromas to the retroperitoneal space
[12, 25].
2.2. Hand-Assisted Laparoscopic Nephroureterectomy. Apart
from standard laparoscopic nephroureterectomy among
urologists, hand-assisted laparoscopic nephroureterectomy
is also an acceptable technique [18, 20]. Patient preparation
and positioning is identical to that described for transperi-
toneal LRN (laparoscopic nephroureterectomy). The hand-
assisted LRN technique usually begins with a 6cm to 8cm
incision for hand-port placement through a lower quadrant
Gibson-type incision (Figure 3(a)) or through the lower
midline abdomen (Figure 3(b)). The Kawauchi et al.’s [18]
experience was described in 34 consecutive patients who
underwent hand-assisted laparoscopic nephroureterectomy
using a Lap Disc (Hakko Shoji, Tokyo, Japan). Those 34
patients were compared with the previous group of 34
patients who underwent open nephroureterectomy. Mean
follow-up was 13.1 months in the hand-assisted group and
48.8 months in the open group [18]. In the hand-assisted
group, there was observed a similar operative time (233 ver-
sus 236 minutes), decreased analgesia frequency (2.1 versus
4.1 days), decreased blood loss (236 versus 427mL), quicker
return to ambulation (1.5 versus 2.5 days), and shorter
hospital stay (13 versus 21.1 days). In the Japanese series
compared with the American ones, the lengthy stayis a social
issue and not reﬂective of actual patient recovery. There
were 4 (12%) complications in both groups, with 1 open
conversion in the hand-assisted group. The 4 complications
in the hand-assisted group include 1 conversion due to
bleeding from the left adrenal gland, 2 wound infections,
and 1 pulmonary infarction in a patient who recovered with
conservative treatment [18]. As regarding the histological
tumor grade, the pathologic studies have revealed that in
the hand-assisted group there were 5, 20, and 9 patients
with grades 1, 2, and 3 tumors, whereas in the open group
there were 4, 17, and 13 patients with grades 1, 2, and 3
tumors, respectively. Recurrence rate was 12% (4 patients)
in the hand-assisted group, with a mean time to recurrence
of 9.5 months. Patients in the open group had a longer mean
time to recurrence at 14.4 months, with a 47% (16 patients)
recurrence rate [18].
Seifman et al. [26] completed a prospective study
comparing 16 patients (mean follow-up, 19 months) who
underwent hand-assisted laparoscopic nephroureterectomy4 Advances in Urology
(a) (b)
Figure 3: (a) Right lower quadrant hand-port placement for hand-assisted right radical nephrectomy, and (b) Lower midline hand-port
placement for hand-assisted right radical nephrectomy.
to 11 patients (mean follow-up 16 months) who underwent
the open technique. Despite the fact that the operative
time was longer in the hand-assisted group (320 versus 199
minutes), there was a decrease in the length of hospital stay
(3.9versus5.2days),timetooralintake(33versus38hours),
analgesic requirements (20 versus 31 tablets), and return
to normal activity (18 versus 38 days). Tumor recurrence
appeared in 3 of 16 laparoscopic cases and in 7 of 11 open
cases. However, the open series had a higher number of
patients with grade 3 (6 of 11) and T3 disease (5 of 11)
compared with the laparoscopic group (5 of 16 with grade
3, 3 of 16 with T3 disease).
Landman et al. [20] compared 16 patients who under-
went hand-assisted laparoscopic nephroureterectomy to 11
patients who underwent a standard one. In the standard
group, the mean follow-up was 27.4 months, whereas in
the hand-assisted group it was 9.6 months. Compared with
the standard technique, patients who underwent the hand-
assisted technique had a decreased operative time (4.4 versus
5.3 hours), similar blood loss (201 versus 190mL), longer
time to oral intake (20 versus 13 hours), similar analgesic
use (33 versus 29.3mg of morphine), longer hospital stay
(4.5 versus 3.3 days), and longer time to complete recovery
(8 versus 5.2 weeks).
Complications occurred in 5 patients in both groups,
with 1 open conversion in the hand-assisted group due to
failure to progress. Myocardial infarction and respiratory
failure was the cause of death postoperatively for a patient
in the hand-assisted group. Pathologic stage and grade
were similar in the 2 groups, with the majority of patients
having low-grade and low-stage tumors. Metastatic disease
developed in 3 out of 15 hand-assisted cases and in 2 patients
of the standard group [20].
The results of the trails that compare hand-assisted
laparoscopic nephroureterectomy with other techniques are
summarized in Table 2. Thereafter, these studies sustain the
utility of both hand-assisted and pure laparoscopic tech-
niques fornephroureterectomy. The hand-assisted technique
has the advantage of the tactile sensation and blunt-manual
dissection. The probability of cancer control is similar to
open techniques. However, due to the fact that most of the
studies were current, long-term action—a ﬁve-year period—
is required for deﬁnitive results.
2.3. Robotic-Assisted Laparoscopic Management of Upper
Urothelial Tract TCC. The daVinci robotic surgical system
has revolutionized minimally invasive urologic laparoscopy
as applied to prostatectomy. By providing a three-
dimensional operating environment and instrumentation
with two additional degrees of freedom, the daVinci
surgical system appears to have dramatically reduced the
learning curve for complex-laparoscopic procedures. Even
laparoscopically inexperienced open surgeons can become
remarkably talented in a technically challenging procedure
such as robotic radical prostatectomy in as few as 12 patients
[27].
Since there are not any studies regarding the robotic-
assisted laparoscopic management of upper urothelial tract
carcinoma, we analyze the papers of robot-assisted laparo-
scopicpartialnephrectomyandwebelievethatthetechnique
will be soon applicable for small lesions of renal pelvis and
upper ureter.
The ﬁrst series of robot-assisted laparoscopic partial
nephrectomy (RLPN) for small renal masses was reported
by Gettman et al. [28]. Since then, there have been ﬁve
other reports, three of which detail the New York University
experience [29–33]. The results of the last trail conducted
by Deane et al. [33] as regarding the mean tumor size,
the mean total procedure time, the mean estimated blood
loss, and the mean warm ischemia time are similar to those
analyzed in the previously reported series, and by comparing
them with laparoscopic partial nephrectomy (LPN), there
were no diﬀerences. Moreover, in this cohort there were no
conversions, while in the New York University series, among
12 patients, there were two conversions: one to a hand-
assisted approach and one to an open approach [30]. In the
series of Kaul et al. [32], like in that of Deane et al. [33],
there were no conversions; however, a patient had urgent re-
exploration and nephrectomy. These studies are summarized
in Table 3.Advances in Urology 5
Table 2: Studies that compare hand-assisted laparoscopic nephroureterectomy with other techniques.
Study No. of
patients Tumor grade Follow-up Outcomes
Kawauchi et al. [18]
34 in
HALN 34
in OS
24 patients in HALN
arm and 25 in OS arm
grade II
13.1 months in
HALN,48.8 in OS
TTR for HALN 9.5 months
with RR 12% TTR for OS
14.4 months with RR 47%
Seifman et al. [26]
16 in
HALN 11
in OS
12 patients in HALN
a r ma n d9i nO S
grade II tumors
19 months in
HALN,16 in OS
TR for HALN in 3 patients
and for OS in 7 patients
Landman et al. [20]
16 in
HALN 11
in LN
13 patients in HALN
a r ma n d8i nL Na r m
grade III tumors
9.6 months in
HALN,27.4 in LN
HALN decreases operative
time without signiﬁcantly
altering short-term
parameters of
convalescence
HALN: hand-assisted laparoscopic nephroureterectomy, LN: laparoscopic nephroureterectomy, OS: open surgery, TTR: time to recurrence, RR: recurrence
rate, TR: tumor recurrence.
RLPN using the daVinci surgical system can be per-
formed by a fellowship of trained urologic oncologists with
extensive experience in robotic radical prostatectomy; early
results mirror those achieved by experienced laparoscopic
surgeonsperformingstandardLPN.Theseresultscanfurther
support the assumption of introducing a robotic interface
which provides surgeons with extensive experience in open
and other robotic procedures (in this instance, open partial
nephrectomyandrobot-assistedradicalprostatectomy),with
thesuccessfulincorporation of advanced robotic procedures,
such as partial nephrectomy, into their clinical practice.
2.4. Management of Distal Ureter and Bladder Cuﬀ. While
there is a negligible disagreement about the role of laparo-
scopic nephroureterectomy, the management of the distal
ureter and bladder cuﬀ with laparoscopy varies among
the surgeons. Techniques include (1) open excision, (2)
transvesical laparoscopic detachment and ligation technique,
(3) laparoscopic stapling of the distal ureter and bladder, and
(4) the “pluck” technique. Steinberg and Matin have recently
reviewed these techniques [21].
2.4.1. Open Technique. An open technique involves initial
dissection of the renal unit laparoscopically. After its com-
pletion, the ureter is clipped but not ligated to avert potential
downstream seeding of tumor cells. Once the laparoscopic
ports are separated, either a midline, Gibson, or Pfannen-
stiel incision is performed. The distal ureter is identiﬁed
and dissected towards the bladder. The specimen is then
isolated en bloc with a border of bladder cuﬀ. The bladder
may be opened and the ureter dissected intravesically and
extravesically, or secured and the full dissection performed
extravesically.
Matsui et al. [22]reportedtheirresultsin17patientswho
underwent laparoscopic nephroureterectomy using an open
technique to remove the distal ureter and bladder cuﬀ.A
comparison with another 17-patient group who underwent
standard nephroureterectomy was performed. The mean
follow-up was 8.8 months in the laparoscopic group and
23.0 months in the standard group. Patients who were in
high risk and had good performance status had received
adjuvant chemotherapy postoperatively. In the laparoscopic
group, 1, 6, and 10 patients had grades 1, 2, and 3 diseases
on ﬁnal pathologic examination. The standard group had
0, 6, and 11 patients with grades 1, 2, and 3 diseases on
ﬁnal pathologic examination. T3 disease was found in 5
patients in both groups with the rest of patients having T2
or lower disease. Three patients in the laparoscopic group
and four in the standard group, respectively, had received
adjuvant chemotherapy. The recurrence was observed only
in a patient in the laparoscopic group, in comparison to six
in the standard group, but that could be attributed to the
shorter follow-up of the laparoscopic group. After adjusting
to that diﬀerence in follow-up, there were no signiﬁcant
diﬀerences in the disease-free survival rate between the 2
groups [22].
Klingler et al. [16] also reported on 19 patients who
underwent laparoscopic nephroureterectomy; mean follow-
up 22.1 months, with an open approach to remove the
distal ureter and bladder cuﬀ. The comparison was made
to 15 patients who underwent standard nephroureterectomy,
mean follow-up 23.1 months. According to the T stage,
there were 12 patients with T1 versus 10, 2 patients with
T2 versus 2, and 5 with T3 versus 3 in the laparoscopic
and standard groups, respectively. Tumor recurrence was
observed in a patient in both groups who had grade 3 and
T3 disease. This study also concluded that the risk for tumor
recurrence and cancer control rates was similar between the
standard technique and the laparoscopic group with an open
technique of handling the distal ureter and bladder cuﬀ.
2.4.2. Transvesical Laparoscopic Technique. Gill et al. [23]
haveusedatransvesicallaparoscopictechniquetoremovethe
distal ureter and bladder cuﬀ. That was performed by using
2 needlescopic ports placed suprapubically into the bladder
under cystoscopic guidance. The patient was repositioned
into the dorsal lithotomy position before placing the bladder
ports. A ureteral catheter was then placed in the ipsilateral
oriﬁce through an endoloop that was passed through the
laparoscopic bladder ports. A grasper was used to tent the6 Advances in Urology
Table 3: Studies for robotic-assisted laparoscopic nephrectomy.
Study No. of patients Conversions Follow-up Outcomes
Gettman et al. [28] 13 1 to LN 13 months
RALN is feasible and safely
performed
Phillips et al. [30] 1 2 2o n et oH A L Na n d1t oO S 1 2m o n t h s
RALN is safe, feasible, and
reproducible
Caruso et al. [31] 10 1 to LN 12 months
RALN safe and feasible
procedure in patients with
small exophytic masses
Kaul et al. [32] 10 No conversions 15 months
RALN is a viable alternative
to LN for patients with
small exophytic masses
Deane et al. [33] 10 No conversions 16 months
No diﬀerence between
RALN and LN as regarding
PT,IBL and MWIT
RALN: robotic-assisted laparoscopic nephrectomy, LN: laparoscopic nephrectomy, OS: open surgery, PT: procedure time, IBL: intraoperative blood loss,
MWIT: mean warm ischemia time.
ureter anteriorly and a Collins knife to dissect the bladder
cuﬀ and ureter. The intramural ureter and bladder cuﬀ
were completely detached en bloc from the bladder. The
dissection continued with the Collins knife into the pelvic
extraperitoneal fatty tissues.
Gill et al. [12] compared 42 patients who underwent that
technique to 35 patients who underwent the standard open
nephroureterectomy.Thatstudy-casewasdiscussedearlierin
this study and as a conclusion the patients had comparable
cancer-speciﬁc survival and tumor recurrence. The follow-
up, however, was shorter for patients who underwent the
transvesical laparoscopic technique.
Stifelman et al. [34] have also reported using a combined
transvesical laparoscopic and endourologic technique on
22 patients with an average follow-up of 13 months. The
pathologic examination has revealed that 3, 10, and 9
patients had grades 1, 2, and 3 tumors. Five lesions were
Ta, 8 were T1, 2 were T2, and 7 were T3 disease. In
all cases, the margins were negative. Disease recurrence
was observed in six patients: four with low grade, low-
stage bladder tumors, not involving the resection site, and
two with grade III T3 tumors who presented later with
metastatic lesions. All patients were alive at 18 months. This
technique simulates established open principles for upper
tract urothelial tumors. Potential criticisms of this technique
are the risk of ﬂuid extravasation and subsequent potential
tumor seeding. This is minimized, however, by continuous
suction from the transvesical ports. Furthermore, a meta-
analysis of the literature reveals no reports of tumor seeding
in over 50 patients to date [12, 21, 23, 34, 35]. In cases
in which tumor is presented in the distal and intramural
ureter, active bladder disease exists, and in patients who
have received prior pelvic radiation therapy this technique
is contraindicated.
2.4.3. Laparoscopic Stapling Technique. Laparoscopic sta-
pling of the distal ureter and bladder cuﬀ has been combined
with cystoscopic unrooﬁng [13, 21]. With this procedure,
ureteral unrooﬁng is performed initially via cystoscopy
and placement of a balloon catheter in the intramural
ureter. The distal ureter and bladder cuﬀ are then stapled
laparoscopically during the distal dissection, using an Endo-
GIA (US Surgical, Norwalk, Conn, USA) stapler.
Shalhav et al. [13] reported their experience using
the laparoscopic stapling technique in 25 patients who
underwent laparoscopic nephroureterectomy and compared
them with 17 patients who underwent open radical
nephroureterectomy. A patient in the laparoscopic group
underwent the “pluck” technique, which will be discussed
later in this review. Mean follow-up was shorter in the
laparoscopic group (24 versus 43 months). Thirteen patients
in both groups had grade 2 disease or greater. Distal
metastases developed in 4 patients (31%) in the laparoscopic
group and 3 patients (23%) in the open group. In the
laparoscopic group, local recurrence rate was lower, 3 versus
7, but this could be attributed to a shorter follow-up. All
patients with recurrence in the laparoscopic group had
tumors that recurred in the bladder and were treated with
transurethral resection. The authors argue in this series that
the stapling technique minimizes the risk of tumor spillage,
since the bladder cuﬀ just caudal to the ureter is secured and
occluded with six rows of titanium staples before it is incised.
Yoshino et al. [37] also reported their experience with 23
patients using ﬂexible endoscopic gastrointestinal automatic
stapler (Ethicon Endosurgery, Cincinnati, Ohio, USA) in
their laparoscopic series. At a mean follow-up period of
15 months, 4 patients had bladder recurrence which was
successfully treated by transurethral resection. Three of
those patients had no evidence of disease at greater than
a 20-month-follow-up, whereas 1 died of other medical
comorbidities.
Whilethepreviousstudiessupporttheuseofthestapling
technique for distal ureteral and bladder cuﬀ management,
Matin and Gill [35] evaluated outcome and patterns of
recurrence based on the form of bladder cuﬀ control.
They concluded that positive margins were higher with aAdvances in Urology 7
Table 4: Studies that compare techniques for the management of distal ureter end bladder cuﬀ with other methods of treatment.
Study No. of
patients Tumor grade Follow-up Outcomes
Open technique
Matsui et al. [22] 17 in OT
17 in SN
14 patients OT arm
a n d1 3i nS Na r m
grade III
8.8 months in OT
and 23 months in
SN
No diﬀerence in DFS
Klingler et al. [16] 19 in OT
15 in SN
15 patients in OT and
13 in SN arm grade II
21.1 months in OT
and 23.1 months in
SN
CCR and RTR similar in
both arms
Transvesical laparoscopic technique
Gill et al. [12] 42 in LT
35 in SN
34 patients in LT arm
a n d2 8i nO Sa r mI I I
tumors
11.1 in LT and
34.4 months in SN
CSS and TR comparable in
both arms
Laparoscopic stapling technique
Shalhav et al. [13] 25 in LT
17 in SN
21 patients in LT arm
a n d1 4i nO Sa r m
grade II
24 months LT
43 months SN RTR lower in LT
The “pluck” technique
McNeill et al. [36] 25 in PT
42 in SN
18 patients in PT arm
grade II and 36
patients in SN arm
grade III
32.9 months PT
42.3 months SN No diﬀerence in TR
SN: standard nephroureterectomy, OT: open technique, CCR: cancer control rate, RTR: risk of tumor recurrence, CSS: cancer speciﬁc survival, TR: tumor
recurrence, ORN: open radical nephroureterectomy, PT: “pluck” technique.
laparoscopic stapling approach than either the open or the
transvesical technique. Additionally, the stabling technique
was associated with poorer recurrence-free survival.
The theoretical risk of stone formation, secondary to
the migration of staples into the bladder mucosa, could be
an additional animadversion of this technique. Chandhoke
et al. [38] reported that there was neither stone formation
nor visible staples in the bladder after using the stapling
technique. A recent case report revealed the presence of a
nearly complete intravesical titanium staple line on surveil-
lance cystoscopy at a follow-up of 6 months [39]. However,
there was no identiﬁable encrustation in that patient, and
a successful transurethral resection of the staple line was
performed without sequela.
2.4.4.The“Pluck”Technique. The“pluck”techniqueinvolves
anaggressivetransurethralresectionoftheipsilateralureteral
oriﬁce with a simultaneous “plucking” of the distal ureteral
during the laparoscopic procedure. Before the resection of
the renal unit and ureter, this resection is performed initially
viaar esectosc ope.M cN eiletal.[36]treated25patientsusing
that technique and compared them with 42 patients who
underwent open nephroureterectomy. In the laparoscopic
group, the follow-up was shorter mean 32.9 versus 42.3
months. According to tumor grade, in the laparoscopic
group, there were 4, 6, and 9 patients with grades 1 and
2, while in the open group there were 2, 8, and 6 patients
with grade 3. Pathologic examination also revealed T1, T2,
and T3 diseases in 0, 1, and 9 patients in the laparoscopic
group and 0, 3, and 6 patients in the open group. Four
deaths in the laparoscopic group and nine in the open group
were observed. The authors concluded that there was no
increase in local recurrence within the laparoscopic group
during the follow-up, but the exact incidence of recurrence
wasnot reported. The studies thatcomparethe techniques of
the management of distal ureter and bladder cuﬀ with other
methods of treatment are summarized in Table 4.
The major criticism of that technique is tumor seed-
ing and the potential to leave behind a segment of an
incompletely resected ureter [21, 40–42]. Arango et al. [40]
described a case of a fatal recurrence at the resection site
after endoscopic resection of the intramural ureter. The
patient had stage 1 grade 2 transitional cell carcinoma with a
normallowerureterandbladder.Nevertheless,sevenmonths
later, the patient presented with pelvic pain and urgency.
Computed tomography revealed a large vesical mass at the
site of the resected lower ureter. The biopsy showed a grade 3
tumorstageIVandthepatientunderwentsalvagecystectomy
with adjuvant chemotherapy. Three months after cystectomy
the patient died. The exact incidence of tumor seeding is
unknown and diﬃcult to assess. On the other hand, the
theoreticalpotentialcombinedwiththeabovereportshasled
some authors to abandon this technique [40–42].
To summarize, laparoscopic nephroureterectomy with
open distal ureterectomy is a safe and acceptable alternative
toopennephroureterectomy.Cancercontrolratesseemtobe
similar with superior convalescence. In terms of managing
the distal ureter and bladder cuﬀ, the open technique is
the most eﬃcacious so as to achieve negative margins and
decreased risk of cancer seeding. However, because of the
relatively small series in the literature (due to the low
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literature is fairly recent (due to recent advances), long-term
follow-up and larger series are necessary to assess cancer-
speciﬁc survival and recurrence rates.
3. Endoscopic Management
Generally, recommendations for endoscopic management
of upper-tract TCC include patients with anatomic or
functional solitary kidneys, bilateral upper-tract TCC, base
line renal insuﬃciency, or signiﬁcant comorbid diseases that
preclude abdominal surgery [43]. Patients with a normal
contralateral kidney who have small, low-grade lesions can
also be reasonable candidates for conservative management
[44]. Endoscopic treatment of the upper urinary tract can
be performed via either a retrograde ureteroscopic or a
percutaneous antegrade approach.
As regarding the retrograde ureteroscopic, an approach
can be used for low-volume ureteral and renal pelvic tumors.
Proximal ureter and renal pelvic lesions require ﬂexible
ureteroscopes, while tumors localized in the intramural and
distal ureter are best managed by rigid ureteroscopy [45].
Low morbidity in association with maintenance of urothelial
integrity is the principal advantage of retrograde endoscopy
[43, 45, 46]. This technique is limited, however, by the size of
instruments that can be accommodated in the ureter, which
inturnlimitsthesizeoftumorthatcanbeadequatelytreated.
Some portions of the upper urinary tract, such as the lower
pole calyces, are less accessible by a retrograde approach.
Furthermore,retrogradeureteroscopydiﬀersinpatientswho
have undergone a prior urinary diversion.
An initial biopsy of the lesion is required for the
ureteroscopic method followed by a debulkment to its base
using cold-cup forceps (3Fr or 5Fr) or a stone basket (1.9Fr
or 2.4Fr) [45]. Due to the fact that the wall of the proximal
ureter and renal pelvis is thin, no attempt should be made
to resect these regions deeply. The base of the lesion is
subsequentlyaddressedbymonopolarelectrocauteryorlaser
ablation (neodymium: yttriumaluminum-garnet [Nd:YAG]
or holmium [Ho]: YAG laser) [47]. With a tissue penetration
of less than 0.5mm, the Ho:YAG laser is well suited for use
in the ureter, allowing for excellent hemostasis with minimal
transmural thermal damage. Conversely, the Nd:YAG laser
has a deeper penetration (5-6mm) making it better suited
for coagulative necrosis of large lesions, particularly in the
r e n a lp e l v i s[ 46].
Ureteral perforation and postoperative strictures are
the principal complications associated with retrograde
ureteroscopy. The incidence of perforation in most series is
below 10% and is readily managed by ureteral stenting or
percutaneous nephrostomy drainage [48, 49]. The reported
stricture rate following retrograde management of upper-
tract TCC ranges from 4.9% to 13.6% [48–50]. Literature
data indicate that a lower incidence of strictures is associated
with lesions managed by laser ablation, rather than with
electrocoagulation [51]. Most postoperative strictures are
successfully managed by endoscopic stenting, laser incision,
or balloon dilatation. Ultimately, all ureteroscopic interven-
tions should be followed with short-term ureteral stenting to
prevent postoperative obstructive sequelae.
Nevertheless, being more invasive than retrograde ure-
teroscopy, the percutaneous antegrade approach is preferred
in larger tumors of the renal pelvis and proximal ureter.
Antegrade nephroscopy oﬀers better visualization of the
renal pelvis whereas accommodating larger caliber working
instruments, being able to handle a larger tumor burden.
The percutaneous approach also allows for superior access
to the lower pole calyces, as well as to renal units with
complicated calyceal anatomy. The principal disadvantage
of this approach is violation of urothelial integrity with
reports of tumor seeding of nonurothelial surfaces around
thekidneyorinthenephrostomytract[52,53].Largerseries,
however, fail to note such tract recurrences, conﬁrming that
this phenomenon is uncommon [54–56].
After a percutaneous tract that can accommodate a 30
Fr access sheath is subsequently established, the lesion is
initially biopsied and consequently debulked. Due to the
larger access tract, antegrade techniques permit the use of
cold-cup biopsy forceps through a standard nephroscope or
a cutting loop from a resectoscope. The base of the lesion
is resected and sent separately for staging purposes, and
haemostasis is achieved by electrocautery or laser ablation
as previously described. The established nephrostomy tract
can be maintained, allowing for repeated treatment or
administration of topical adjuvant therapy [45, 46].
Away from tumor tract seeding, complications of percu-
taneousmanagementofupper-tractTCCaresimilartothose
of percutaneous stone procedures and include bleeding,
infection, electrolyte abnormalities, adjacent organ injury,
and pleural injury [45, 46].
The safety and eﬃcacy of ureteroscopic management of
upper-tract TCC are conﬁrmed by multiple studies. In 1997,
Tawﬁek and Bagley reported on the outcomes of 205 patients
summarized from 14 modern series and found a recurrence
rate of 33% for 61 renal pelvic tumors and 31% for 144
ureteral tumors [57]. More recent reviews demonstrate
similar ﬁndings, with recurrence rates ranging from 31%
to 65% and disease-free rates of 35% to 86% [47, 49, 58–
62]. The bladder was the most frequent site of recurrence
in these series. Tumor recurrence was most dependent upon
pathologic grade with recurrence rates of 25% for grade I
tumors and almost 50% for higher-grade lesions [48]. It is
important to note that initial endoscopic management does
not predict a worse outcome if disease progression occurs.
Boorjian and colleagues reported that ureteroscopic tumor
ablation before nephroureterectomy did not adversely aﬀect
postoperative disease status [63].
As regarding the percutaneous approaches, they have
promising results when taking into consideration that
these lesions are more substantial than those managed by
retrograde ureteroscopy. Okada et al. performed a review
in 84 patients and found an overall recurrence rate of
27%, with tumor grade strongly predicting outcomes [64].
Additionally,Rouprˆ etetal.reportedasimilarrecurrencerate
ofapproximately30%,with5-yeardiseasespeciﬁcsurvivalof
almost 80% [65] .M o r e o v e r ,L e ee ta l .r e v i e w e dt h e i r1 3 - y e a r
experience with percutaneous management of upper-tract
TCC patients and found no signiﬁcant diﬀerences in overall
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nephroureterectomy [66]. Regardless of treatment modality,
patients with low-grade lesions did well, while those with
high-grade tumors were predisposed to tumor recurrence
and progression.
The recommended follow-up of patients treated for
upper-tract TCC should consist of interval history and
physical examination, urinary cytology, and surveillance cys-
toscopy every 3 months for the ﬁrst 2 years after treatment,
every6monthsforthenext2yearsandyearlythereafterifthe
patient is free from disease recurrence [46, 67]. Radiographic
studiesincludingchestX-rayandabdominopelvicCTshould
be performed every 6 months for the ﬁrst 2 years and yearly
thereafter. Ipsilateral endoscopy for patients who undergo
organ-sparing treatment should occur every 6 months for
the ﬁrst 2-3 years and yearly thereafter, provided that the
patient is disease free. Bone scans should only be performed
for symptoms of bone pain or for an elevated alkaline
phosphatase level.
4.ThePrognosticV alueofLymphadenectomyin
Patients with Muscle Invasion
Patients with muscle-invasive transitional cell carcinoma of
the upper urinary tract are at high risk of nodal metastasis,
andtheprognosismaybeextremelypoorinthecaseofnodal
involvement [68, 69].
The impact of lymph node dissection on clinical out-
c o m e si sr e p o r t e do n l yi nf e wp a p e r s .K o m a t s ue ta l .[ 68]
evaluated a limited cohort of 36 patients and suggested that
lymph node dissection may provide a therapeutic beneﬁt by
selecting patients with lymph node metastasis as candidates
for adjuvant therapy. Miyake et al. [70]r e p o r t e do n7 2
patientswithtransitionalcellcarcinomaoftheupperurinary
tract. 35 of those had undergone total nephroureterectomy
and regional lymphadenectomy. Lymph node dissection
was associated with an increased cancer-speciﬁc survival
in patients with no evidence of lymph-vascular invasion.
On the other hand, in patients with evidence of lymph-
vascular invasion who were considered at higher risk of
micrometastatic disease, no additional prognostic advan-
tages were provided by lymph node dissection.
In contrast, no data is available on the extent of lymph
node dissection in patients with invasive transitional cell
carcinoma of the upper urinary tract.
Recently, Brausi et al. [71] showed that in patients
with muscle-invasive transitional cell carcinoma of the
upper urinary tract, disease-free survival and cancer-speciﬁc
survival were signiﬁcantly higher in patients who had
retroperitoneal lymph node dissection in conjunction with
nephroureterectomy than in patients who did not undergo
lymph node dissection. They recommended that an accurate
and extended lymph node dissection can be curative in
patients with advanced transitional cell carcinoma of the
upper urinary tract. Nevertheless, they did not analyze the
impact of the number of removed lymph nodes on clinical
outcome.
Roscigno et al. [72] ﬁrst tested the role of lymph node
dissection on disease-free survival and cancer-speciﬁc sur-
vival. They observed 132 consecutive patients with muscle-
invasive transitional cell carcinoma of the upper urinary
tract who underwent radical surgery. Lymph node dissection
was performed in 95 cases. Patients were stratiﬁed according
to the presence of lymph node dissection and lymph node
status.
They concluded that patients undergoing lymph node
dissection at the time of radical surgery had a signiﬁcantly
better prognosis, contrary to those managed with tumor
excision only, even though, in the group of patients under-
going lymph node dissection, about 1/4 (26 patients) had
nodal metastases. Then, they analyzed the clinical outcome,
according to nodal status. They observed that the prognosis
of patients who did not receive lymph node dissection (pNx)
was signiﬁcantly worse than that of pN0 patients, whereas,
interestingly, both disease-free survival (DFS) and cancer-
speciﬁc survival (CSS) of pNx patients were comparable to
those of pN+ patients. This was conﬁrmed at multivariable
analysis, where lymph node status emerged as a signiﬁcant
predictor of DFS and CSS after accounting for age at
diagnosis, T stage, G grade, CIS (cancer in situ), LVI
(lymph-vascularinvasion), yearofsurgeryand postoperative
chemotherapy.
These data are in contrast with those presented by a
recent paper of Brown et al. [73], showing that survival
of Nx and N0 patients is similar and signiﬁcantly higher
than N+ patients. On the other hand, the M. D. Anderson
series evaluated superﬁcial tumor also, whereas in this
series only muscle-invasive transitional cell carcinomas were
considered. Probably in their population a higher percentage
of pNx patients could have had positive nodes if lymph node
dissections were performed.
Finally, these results suggest for the ﬁrst time that the
number of lymph nodes removed and examined, related
to the extent of lymph node dissection, seems to play a
signiﬁcant role in predicting clinical outcome after radical
surgery. In fact, even when only the subset of patients
managed with lymph node dissection was analyzed, the
number of lymph nodes removed and examined emerged,
both in invariable and multivariable analyses, as a signiﬁcant
predictor of DFS and CSS, independently from the evidence
of nodal metastases. A better clinical outcome was observed
in those patients in whom at least six lymph nodes had been
removed and examined [74].
5. AdjuvantTherapy
5.1. Immunotherapy. More than one third of the patients
with endoscopically treated upper tract TCC will develop
tumor recurrence [46]. In order to reduce recurrence rates,
adjuvant topical immunotherapy or chemotherapy can be
used. There are several methods to perform an instillation:
by infusion through a percutaneous nephrostomy tube, via
a retrograde ureteral catheter, or by retrograde reﬂux from
the bladder with an indwelling double-J stent, or by surgical
creation of ureteral reﬂux. The aim of the treatment is a
continued exposure of the urothelium to the topical agent
while maintaining a low-pressure system that is free of
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such as sepsis, although granulomatous changes in the
kidney and systemic adverse eﬀects relating to bacillus
Calmette-Guerin (BCG) infection can occur [75, 76].
The same agents used to treat urothelial carcinoma of the
bladder can be used to treat tumorsof the upper tracts. The
most common agents instilled are BCG or mitomycin-C.
Asregardingthespeciﬁcroleofuppertractimmunother-
apy and topical chemotherapy, there are few reports in the
literature. Thalmann et al. [77] reported on 41 renal units
treated in 37 patients with BCG (Bacillus Chalmette-Guerin)
via percutaneous nephrostomy tube with a mean follow-up
of 44 months. For carcinoma in situ (CIS), there were treated
25 renal units and another 16 received adjuvant BCG therapy
for superﬁcial tumors in 15 patients. In this study no tumor
seeding occurred along the nephrostomy tract. Indications
for treatment in this study included solitary renal units,
renal insuﬃciency, bilateral disease, and inoperable disease.
Among the patients with CIS, 9 died of disease (41%), 6 died
of other causes (27%), and 7 are alive at a median follow-
up of 50 months (32%). Median overall survival and time
to recurrence were 44 and 25 months, respectively. Fifteen
patients with papillary disease of the urinary tract in 16 renal
units were treated (TaG1 in 2, TaG2 in 6, TaG3 in 2, T1G3 in
2, and Tx in 4). Overall survival was 40 months (range of 1–
59). Thirteen patients (87%) had recurrence after a median
interval of 10 months (range of 1–69) and progression after
a median interval of 11 months (range of 5–27). Among
the 15 patients, 4 are alive, 6 died of disease, and 5 died
of other causes with tumor present in the upper urinary
tract.
The authors concluded that papillary and solid tumor
recurrencesoftheupperurinarytractcouldnotbeprevented
with BCG therapy. However, BCG therapy did provide cure
in approximately 50% of renal units with CIS. Several other
studies also support the use of BCG for upper tract CIS [78–
83].
Vasavada et al. [84] also reported on the use of BCG in
the adjuvant setting for upper tract urothelial tumor. After
surgical resection for upper tract transitional cell carcinoma
ineightpatients,theyreceivedadjuvantBCGtherapy.Grades
1, 2, and 3 diseases were present in 2, 5, and 1 patients,
and Ta, T1, and T2 diseases occurred in 5, 2, and 1 patients
in this cohort. At a mean follow-up of 23.8 months, 5
out of 8 patients (62.5%) were disease free, 2 out of 8
patients (25%) died of disease, and 1 out of 8 (12.5%)
was alive with metastatic disease and receiving systemic
chemotherapy.
Although the study number was small, the authors
concluded that the application of BCG after deﬁnitive
resection of the primary tumor may result in a decreased
incidence of local tumor recurrence.
To our knowledge, there has not been any randomized,
prospective, placebo-controlled trial speciﬁcally addressing
the eﬀectiveness of topical immunotherapy or chemotherapy
for adjuvant treatment of upper tract urothelial tumors [77–
85]. Until such studies become available, adjuvant therapy
may be used in patients undergoing nephron-sparing man-
agement of upper tract transitional cell carcinoma with their
consent and the addition of a strict surveillance protocol.
5.2. Radiation Therapy and Systemic Chemotherapy. The fact
thatthetransitionalcellcarcinomaoftheupperurinarytract
is relatively rare has led to a scarcity of studies that analyze
adjuvant radiation therapy and chemotherapy for locally
advanced but completely resected upper tract urothelial
tumors. When the tumor extents beyond the muscular, the
5-year-survival rates will be between 0% and 34% [5, 9, 86,
87]. The loco-regional recurrence at 5 years after treatment
with deﬁnitive surgery, when no adjuvant chemotherapy was
given, has been reported at several studies between 45% and
60% [88–90]. This high recurrence rate has been a strong
argument for adjuvant therapy for all patients with locally
advanced disease even after complete resection.
However, all recent studies count on limited numbers
of patients because of the rarity of this disease. Some
researches have supported [88, 89, 91] the role of adjuvant
radiation treatment on upper tract urothelial malignancies
and others have rejected it [92, 93]. The role of adjuvant
chemotherapy alone for transitional cell carcinoma also
remains controversial [94].
Maulard-Durdux et al. [92] reported their experience
on postsurgical irradiation in 26 patients with upper tract
tumors after complete resection. 11 patients had stage B
disease (muscular invasion) 42% and 15 patients had stage
C disease (periureteral fat invasion) 58%. According to
tumor grade, 10 patients had grade 2, 40%, 15 had grade
3, 60%, and it was unknown in a patient. The radiation
therapy dose was 45 Gy in all patients. After a mean
follow-up of 45 months, 13 patients (50%) were alive, with
11 patients being disease free. Disease metastasized in 14
patients to the bone, liver, and lungs. The overall 5-year-
survival rates and 5-year survival with no evidence of disease
were 49% and 30%, respectively. The authors concluded that
adjuvant radiation therapy did not improve long-term sur-
vival and is only recommended for prospective randomized
studies.
A recent review of selected series of surgery with or
without adjuvant radiation therapy for carcinoma of the
upper urinary tract revealed some improvement in percent
loco-regional failure [88–90, 92–94]. Six series of patients
who received adjuvant radiation revealed a failure rate
between 9% and 38%. The number of patients ranged from
9 to 45, with 1 series having 86 patients. The 5-year-survival
rate was 21% to 49%. The series of patients who had surgery
only (the number of patients in these series ranged from 11
to 81) without adjuvant treatment had a crude loco-regional
failure rate of 45% to 65% and a 5-year-survival rate of 17%
to 33%. These studies might conclude that with radiation,
there seems to be some improvement in the failure and
survival rate, but large studies need to be performed.
The urothelial tumors of the upper urinary tract are
considered to be chemosensitive tumors [43–45]. Most of
the data regarding the clinical eﬃcacy of chemotherapy
in the neoadjuvant and adjuvant settings are based on
experience from bladder TCC. Advantages of neoadjuvant
chemotherapy include eradication of subclinical metastatic
disease, better tolerability before surgical extirpation, and
ability to deliver higher doses than in the adjuvant setting
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Collaboration and the Southwest Oncology group have pre-
sented compelling data for the use of neoadjuvant platinum-
based chemotherapy regimens before radical cystectomy
[95, 96]. Regimens comprised of gemcitabine and cisplatin
that provide a similar survival advantage to methotrexate-
vinblastine-doxorubicin-cisplatin (MVAC), with a better
safety proﬁle and tolerability, increase the attractiveness
of neoadjuvant chemotherapy [97]. Similar management
strategies are likely to be beneﬁcial for upper-tract TCC,
particularly in the setting of large, bulky tumors.
The role of adjuvant systemic chemotherapy to patients
with locally advanced upper urinary tract tumors is not
well deﬁned, because of the scarcity of controlled trials
due to the low prevalence and incidence of disease. Nev-
ertheless, a recent study by Brown et al. [73]r e p o r t e d
on their experience with both adjuvant radiation therapy
and concurrent chemotherapy for locally advanced disease.
After surgery, 31 patients have received adjuvant radiation
therapy. All patients had grade 2 and even 84% of the
group were found to have a pathologic stage of T3 or
higher. Nine patients received methotrexate, cisplatin, and
vinblastine chemotherapy for 2 to 4 cycles. Univariate
analysis revealed that patients had improved 5-year actuarial
overall and disease-speciﬁc survival with the administration
of concurrent chemotherapy when compared with patients
receivingadjuvantradiationalone(27%versus67%,P = .01;
41% versus 76%, P = .06, resp.).
6. Conclusions
Treatmentofupper-tracturothelialcarcinomahasdeveloped
and changed with advances in technology. Treatment has
evolved from open radical nephroureterectomy to per-
cutaneous resection to ureteroscopic treatment. Adjuvant
treatments are also evolving with topical immunotherapy,
radiation, and chemotherapy. Before any decision for opti-
mal treatment, the speciﬁcs of each individual patient with
regard to renal function, medical comorbidities, location of
disease, tumor stage, and tumor grade must be taken into
account.
Due to the fact that the incidence and prevalence of
this tumor is low, the majority of series in the literature
are of limited number. What is clear from the literature
with regard to surgical outcomes for upper-tract TCC
is that this is a potentially lethal disease if not treated
appropriately. Due to its relative rarity, many decisions
regarding treatment are extrapolated from our experience
in managing bladder urothelial carcinoma (such as node
dissections, topical chemotherapies, immunotherapies, and
adjuvant treatments). The problem about the studies uti-
lizing minimally invasive techniques is that they lack long-
term follow-up. Almost all of the studies are retrospective in
nature and therefore ﬂawed with selection biases.
As a result, the standard way still remains to be surgical
removal with radical nephroureterectomy, and for selected
patients segmental ureterectomy may be performed. Endo-
scopic management is also reasonable in patients with low-
grade and low-stage disease as long as they adhere to a
strict follow-up protocol that includes frequent cytology
and endoscopy. The beneﬁts of adjuvant radiation and
chemotherapy are still debated, but the literature does reveal
some improvement in disease-speciﬁc survival using both
forms of treatment.
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